Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer - XML Representation

Raw xml | Download



<Group xmlns="http://hl7.org/fhir">
  <id value="179619"/>
  <meta>
    <versionId value="4"/>
    <lastUpdated value="2023-12-06T00:11:33.141Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Group</b><a name="179619"> </a><a name="hc179619"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceGroup &quot;179619&quot; Version &quot;4&quot; Updated &quot;2023-12-06 00:11:33+0000&quot; </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-systematic-review-eligibility-criteria.html">SystematicReviewEligibilityCriteria</a></p></div><p><b>Artifact related artifact</b>: </p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>Artifact Title</b>: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer</p><p><b>Artifact URL</b>: <a href="https://fevir.net/resources/Group/179619">https://fevir.net/resources/Group/179619</a></p><p><b>Artifact Publisher</b>: Computable Publishing LLC</p><p><b>Artifact Copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>Artifact use context</b>: <span title="{https://fevir.net/resources/CodeSystem/179423 evidence-communication}">Evidence Communication</span>: <span title="Codes: {https://fevir.net/resources/CodeSystem/179423 SystematicReviewEligibilityCriteria}">SystematicReviewEligibilityCriteria</span></p><p><b>Artifact Contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>CombinationMethod</b>: all-of</p><blockquote><p><b>modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]</b></p></blockquote><p><b>identifier</b>: FEvIR Object Identifier/179619</p><p><b>type</b>: animal</p><p><b>membership</b>: definitional</p><p><b>name</b>: SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer</p><p><b>description</b>: **Study selection criteria**
Types of Studies.
Randomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.

Types of participants.
Patients aged ≥18 years with cytological or histological diagnosis of mHNPC.</p><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: Randomized controlled clinical trials (RCTs)</p><p><b>code</b>: Study Design <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: randomized assignment <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-181513.html">Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide</a>#SEVCO:01003)</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: parallel design</p><p><b>code</b>: Study Design <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: Parallel cohort design <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-181513.html">Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide</a>#SEVCO:01011)</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: compared the association of ADT and chemotherapy (docetaxel), versus ADT alone</p><p><b>code</b>: Comparison <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: <span>: GroupAssignment: ADT plus docetaxel vs. ADT alone</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: Types of participants.
Patients aged ≥18 years</p><p><b>CharacteristicMethod</b>: applied to participants in the studies <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>code</b>: Age <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="https://browser.ihtsdotools.org/">SNOWMED CT</a>#397669002)</span></p><p><b>value</b>: &gt;=18 years<span style="background: LightGoldenRodYellow"> (Details: UCUM code a = 'a')</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: Types of participants.
Patients with cytological or histological diagnosis of mHNPC.</p><p><b>CharacteristicMethod</b>: applied to participants in the studies <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>CharacteristicMethod</b>: cytological or histological diagnosis <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>code</b>: Disease (disorder) <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="https://browser.ihtsdotools.org/">SNOWMED CT</a>#64572001)</span></p><p><b>value</b>: metastatic hormone-naive prostate cancer <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>exclude</b>: false</p></blockquote></div>
  </text>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
    <valueRelatedArtifact>
      <type value="cite-as"/>
      <citation
                value="SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-04. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619."/>
    </valueRelatedArtifact>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Brian S. Alper"/>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-title">
    <valueString
                 value="SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"/>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-url">
    <valueUri value="https://fevir.net/resources/Group/179619"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-publisher">
    <valueString value="Computable Publishing LLC"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-copyright">
    <valueMarkdown
                   value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-useContext">
    <valueUsageContext>
      <code>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="evidence-communication"/>
        <display value="Evidence Communication"/>
      </code>
      <valueCodeableConcept>
        <coding>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="SystematicReviewEligibilityCriteria"/>
          <display value="SystematicReviewEligibilityCriteria"/>
        </coding>
      </valueCodeableConcept>
    </valueUsageContext>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-contact">
    <valueContactDetail>
      <telecom>
        <system value="email"/>
        <value value="support@computablepublishing.com"/>
      </telecom>
    </valueContactDetail>
  </extension>
  <extension
             url="http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method">
    <valueCode value="all-of"/>
  </extension>
  <modifierExtension
                     url="http://hl7.org/fhir/StructureDefinition/artifact-status">
    <valueCode value="active"/>
  </modifierExtension>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="179619"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <type value="animal"/>
  <membership value="definitional"/>
  <name
        value="SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer"/>
  <description
               value="**Study selection criteria**
Types of Studies.
Randomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.

Types of participants.
Patients aged ≥18 years with cytological or histological diagnosis of mHNPC."/>
  <characteristic>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
      <valueMarkdown value="Randomized controlled clinical trials (RCTs)"/>
    </extension>
    <code>
      <text value="Study Design"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/181513"/>
        <code value="SEVCO:01003"/>
        <display value="randomized assignment"/>
      </coding>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
      <valueMarkdown value="parallel design"/>
    </extension>
    <code>
      <text value="Study Design"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/181513"/>
        <code value="SEVCO:01011"/>
        <display value="Parallel cohort design"/>
      </coding>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
      <valueMarkdown
                     value="compared the association of ADT and chemotherapy (docetaxel), versus ADT alone"/>
    </extension>
    <code>
      <text value="Comparison"/>
    </code>
    <valueReference>
      <type value="EvidenceVariable"/>
      <display value="GroupAssignment: ADT plus docetaxel vs. ADT alone"/>
    </valueReference>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
      <valueMarkdown value="Types of participants.
Patients aged ≥18 years"/>
    </extension>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-method">
      <valueCodeableConcept>
        <text value="applied to participants in the studies"/>
      </valueCodeableConcept>
    </extension>
    <code>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="397669002"/>
        <display value="Age"/>
      </coding>
    </code>
    <valueQuantity>
      <value value="18"/>
      <comparator value="&gt;="/>
      <unit value="years"/>
      <system value="http://unitsofmeasure.org"/>
      <code value="a"/>
    </valueQuantity>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
      <valueMarkdown
                     value="Types of participants.
Patients with cytological or histological diagnosis of mHNPC."/>
    </extension>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-method">
      <valueCodeableConcept>
        <text value="applied to participants in the studies"/>
      </valueCodeableConcept>
    </extension>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-method">
      <valueCodeableConcept>
        <text value="cytological or histological diagnosis"/>
      </valueCodeableConcept>
    </extension>
    <code>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="64572001"/>
        <display value="Disease (disorder)"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <text value="metastatic hormone-naive prostate cancer"/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
</Group>